92.9% of metastatic pancreatic cancer patients determined to be KRAS positive using Trovagene's Precision Cancer Monitoring assay

SAN DIEGO, May 13, 2016 -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that clinical study results featuring the Company's Precision Cancer Monitoring® (PCM) platform were presented at the 2016 AACR Special Pancreatic Cancer Meeting in Orlando, Florida. The poster, entitled Detection and Quantification of ctDNA KRAS Mutations from Patients with Unresectable Pancreatic Cancer, was presented by Fernando Blanco, Ph.D., medical science liaison at Trovagene.

TUCSON, Ariz., May 12, 2016  -- HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three months ended March 31, 2016.

 

Recent Accomplishments & Highlights:

 

Entered into a multi-year Collaboration Agreement with Bristol-Myers Squibb (“BMS”) to evaluate immuno-oncology molecular profiling in multiple tumor types and support BMS’s translational research programs

 

Secured distribution agreements with Gamidor Diagnostics (Israel) and Durvis s.l. Parque Tecnologico de Valencia (Spain and Portugal) to manage distribution of HTG’s next generation sequencing (NGS)-based products

SAN CARLOS, Calif., May 10, 2016  -- Natera,  Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2016 and provided an update on recent business progress.

 

Recent Accomplishments & Highlights

 

Generated total revenues of $61.9 million in the first quarter of 2016 compared to $47.4 million in the first quarter of 2015, an increase of 31%

Accessioned greater than 105,000 tests in the first quarter of 2016 compared to approximately 64,000 tests accessioned in the first quarter of 2015, an increase of approximately 64%

Accessioned greater than 81,000 Panorama tests in the first quarter of 2016 compared to approximately 55,000 tests accessioned in the first quarter of 2015, an increase of approximately 47%

IRVINE, Calif., April 21, 2016 -- CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, has begun to explore strategic options including a range of potential M&A and business development opportunities to enhance shareholder value. As part of this effort, CombiMatrix has engaged Torreya Capital, a division of the Financial West Investment Group, Inc. (“Torreya”), to advise the Company and its Board of Directors in this effort.

 

“We are an established player in the diagnostics market and are building on our position as a leader in the growing in vitro fertilization and miscarriage analysis markets with diagnostic tests based on superior technology with clinical and industry support,” stated Mark McDonough, President and Chief Executive Officer of CombiMatrix.  “We are executing on a strategy to drive test volume growth by adding new customers and are securing reimbursement contracts with major payors to assist in maintaining our strong collections rate.